Junji Morimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junji Morimoto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Yoshinori Otsuki
Osaka Medical College
3 shared publications - Eiko Shibata
Laboratory for Drug Discovery Innovation, Department of Molecular Pharmacology, National Cerebral & Cardiovascular Center Research Institute, Osaka, Japan
2 shared publications - Hitomi Kurose
Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Takatsuki, Osaka, Japan
2 shared publications - Kanako Akamatsu
Department of Systems Bioscience for Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
2 shared publications - Masa-Aki Shibata
Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Osaka, Japan
2 shared publications - Jayakrishna Ambati
Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY, USA
1 shared publication
Latest Publications
- Open Access
- 3 June 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 69
α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostanaLinn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation
The mangosteen fruit has a long history of medicinal use in Chinese and Ayurvedic medicine. Recently, the compound α-mangostin, which is isolated from the pericarp of the fruit, was shown to induce cell death in various types of cancer cells in in vitro studies. This led us to investigate the antitumor growth and antimetastatic activities of α-mangostin in an immunocompetent xenograft model of mouse metastatic mammary cancer having a p53 mutation that induces a metastatic spectrum similar to that seen in human breast cancers.
- 3 June 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 69
Open Accessα-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostanaLinn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation
The mangosteen fruit has a long history of medicinal use in Chinese and Ayurvedic medicine. Recently, the compound α-mangostin, which is isolated from the pericarp of the fruit, was shown to induce cell death in various types of cancer cells in in vitro studies. This led us to investigate the antitumor growth and antimetastatic activities of α-mangostin in an immunocompetent xenograft model of mouse metastatic mammary cancer having a p53 mutation that induces a metastatic spectrum similar to that seen in human breast cancers.
- Open Access
- 3 November 2010
- Published by Springer Nature in BMC Medicine
- Vol. 8 (1) , 69
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
Cancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer.
- 3 November 2010
- Published by Springer Nature in BMC Medicine
- Vol. 8 (1) , 69
Open AccessThe endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
Cancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer.
- Open Access
- 19 October 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 566
Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.
- 19 October 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 566
Open AccessRaloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.